Loading…
Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.
Taiwanese clinical-stage biotech developing injectable drugs for localized fat reduction and other aesthetic/dermatology indications.
Has no approved product, so it earns no product sales; it relies on money raised from investors and, if achieved, licensing deals with larger aesthetic-drug companies. Everything depends on trial results and regulatory approval of its injectable fat-reduction drug.
In one line: A Taiwanese peer to Allergan's Kybella developer.
Moat: narrow (IP / patents). Patent-protected injectable drug candidates in a clinical-stage pipeline, unproven commercially.
Headquarters: New Taipei City, Taiwan · Founded: 2012
Size Caliway Biopharmaceuticals (6919.TW) is a Taiwan Health Care company (Biotechnology) with a market value of $3.01B, the 124th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$64.00 on 6 Nov 2026.
Performance Over six months the shares fell 36.6%, against -1.8% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue fell 54.3% over the last twelve months (peer median +5.4%); the operating margin is -6,982.6% (peer median -1.7%).
Valuation It trades at 6,237.3× enterprise value to sales against a peer median of 9.5× (most expensive of 19).
Capital Return on invested capital runs 17.1 points below its cost of capital (7.0% WACC).
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$16.0M | NT$38.0M | NT$44.4M | NT$38.9M | NT$12.8M |
| Revenue growth | — | -14% | +14% | +204% | — |
| Gross profit | NT$11.3M | -NT$4.13M | NT$1.26M | -NT$398,000 | -NT$15.7M |
| EBITDA | n/a | -NT$677M | -NT$688M | -NT$486M | -NT$294M |
| Net income | -NT$611M | -NT$352M | -NT$589M | -NT$488M | -NT$286M |
| Free cash flow | n/a | -NT$442M | -NT$532M | -NT$433M | -NT$257M |
| Capital expenditure | n/a | NT$17.1M | NT$11.1M | NT$9.69M | NT$14.2M |
| Total debt | n/a | NT$3.00M | NT$31.6M | NT$20.5M | NT$28.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Caliway Biopharmaceuticals 6919.TW | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| Evolus EOLS | $449M | +7% | +14% | -7% | 1.8× | n/a |
| InMode INMD | $767M | -5% | -7% | 18% | 0.7× | -10.5% |
| Galderma GALD.SW | $54.8B | +17% | +16% | 19% | 9.9× | 18.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6919.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.8% | -0.4% | 3rd lowest of 21 |
| 6-month return | -36.6% | -1.8% | 3rd lowest of 21 |
| Distance from 52-week high | -66.0% | -27.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | -54.3% | +5.4% | 2nd lowest of 18 |
| Operating margin | -6,982.6% | -1.7% | lowest of 19 |
| EV / Sales | 6,237.3× | 9.5× | most expensive of 19 |
| ROIC minus cost of capital | -17.1 pp | -6.0 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Caliway Biopharmaceuticals 6919.TW | Taiwan | $3.01B | -37% | -54% | -6,983% | 6,237.3× | n/a | n/a |
| HLB 028300.KS | South Korea | $3.06B | -49% | +29% | -96% | 45.9× | n/a | n/a |
| Bavarian Nordic A/S BAVA.CO | Denmark | $2.93B | +27% | -3% | 16% | 2.8× | -2.0% | +27.4% |
| Zai Lab 9688.HK | Hong Kong | $2.92B | +13% | +5% | -59% | 5.5× | n/a | n/a |
| Rubicon Research RUBICON.NS | India | $2.91B | +74% | +37% | 21% | 14.2× | n/a | n/a |
| Sunshine Lake Pharma 6887.HK | Hong Kong | $2.85B | -9% | +20% | -3% | 6.1× | n/a | n/a |
| ADMA Biologics ADMA | United States | $2.85B | +56% | +8% | 42% | 5.7× | -0.8% | +64.6% |
| Denali Therapeutics DNLI | United States | $3.22B | +2% | n/a | -2,488% | 128.0× | n/a | n/a |
| Telix Pharmaceuticals TLX.AX | Australia | $3.22B | -6% | +27% | -1% | 3.9× | n/a | n/a |
| Xeris Biopharma XERS | United States | $2.77B | +133% | +36% | 11% | 8.8× | 33.3% | +70.2% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.76B | -23% | +18% | 27% | 4.7× | 0.5% | +36.0% |
| Beam Therapeutics BEAM | United States | $2.73B | -18% | +163% | -268% | 13.2× | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.71B | -12% | -23% | 5% | 10.3× | 31.3% | -3.8% |
| XtalPi 2228.HK | Hong Kong | $3.35B | -34% | +4% | -127% | 26.3× | n/a | n/a |
| Hualan Biological Engineering 002007.SZ | China | $3.37B | -15% | -11% | 17% | 5.6× | 16.7% | -1.8% |
| Dyne Therapeutics DYN | United States | $3.37B | +3% | n/a | n/a | n/a | n/a | n/a |
| Virbac VIRP.PA | France | $3.38B | +5% | +4% | 15% | 2.1× | 6.2% | +9.4% |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.68B | -52% | 0% | -25% | 21.9× | n/a | n/a |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |
| Disc Medicine IRON | United States | $3.50B | +16% | n/a | n/a | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |